At VERAXA Biotech, we strive to establish the premiere drug discovery and development engine for antibody-drug conjugates (ADCs) and novel antibody-based therapy concepts. By wielding a suite of transformative technological innovations and applying thorough quality-by-design principles in drug discovery, we are accelerating the pipeline through clinical development. VERAXA Biotech originates from scientific discoveries made at the European Molecular Biology Laboratory (EMBL), a world-leading institute for life science research and groundbreaking enabling technologies.

Vision

VERAXA will deliver the next wave of smart cancer therapies with curative potential and far less side effects.

Mission

VERAXA aims to be at the forefront of this smartest generation of antibody-based cancer therapeutics.

We develop cancer programs that are based on:

• antibodies selected for the highest therapeutic value

• an advanced generation of ADCs with never seen flexibility and ease of production

• novel ADCs and our novel BiTAC antibody formats that elevate safety and efficacy to new levels